India’s Biotech Moment: Eyestem CEO bets on fast-tracked cures & global breakthroughs

Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments

NantBioRenewables expands US manufacturing footprint in Alabama

To boost compostable packaging, resin innovation, and supply chain speed

ten23 health expands APAC footprint with new Tokyo office, appoints Noriko Utsumi

Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region

Vir Biotechnology advances VIR-5500 into expansion trials in prostate cancer

Plasmidsaurus expands RNA-Seq in Europe, partners with Genovis for ambient RNA shipping

The dual expansion simplifies transcriptomics workflows by combining faster regional turnaround with easier sample logistics

Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio

The acquisition complements Gilead’s existing oncology expertise and development infrastructure

Stipple Bio raises $100M Series A to advance next-gen cancer therapies

The new capital is expected to fund the company through 2029

Enveric Biosciences bags key US patent for mental health drug

EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes

Biocon renames Irish step-down subsidiary as Biocon Biologics Ireland

Move aligns global biologics identity under the Biocon Biologics brand

Enveda’s experimental oral therapy shows breakthrough results in atopic dermatitis trial

Safety was equally impressive. ENV-294 was well tolerated

Dr Jitendra Singh calls for India-led biosimilar insulin scale-up amid global supply concerns

Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation

Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies

Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy

Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma

The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy

India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push

DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports

Nearly 40 industry groups unite to push for EU Biotech Act II

A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative

Biocon Foundation, BeST Cluster and NCBS launch first BioWISE Cohort for postgraduate women students

Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship

Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million

Orca Bio’s Orca-T FDA review extended to July 2026

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds

Biocytogen partner NEOK Bio gets FDA nod for novel cancer therapy

The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors